Q&A: Ken Song de­tails Rayze­Bio’s path from Se­ries A to IPO in 3 years, tak­ing a down round and be­ing dis­ci­plined

Ken Song al­most nev­er got in­to ra­dio­phar­ma­ceu­ti­cals. But af­ter back-to-back phone calls from ven­ture cap­i­tal lead­ers at Ver­sant and ven­Bio in March 2020, the re­peat …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER